BioLuminate
Antibody and biologics modeling platform
Company profile
Physics-based software platform for molecular discovery and design
Company profile
Schrödinger is a computational platform company that transforms the way therapeutics and materials are discovered through physics-based molecular modeling and simulation. Founded over 30 years ago, the company has built an industry-leading software platform that combines advanced computational chemistry, molecular dynamics, machine learning, and predictive modeling to accelerate molecular discovery across life sciences and materials science applications. The company's flagship products include Maestro (unified modeling environment), Glide (ligand-receptor docking), FEP+ (free energy calculations), LiveDesign (collaborative design platform), Desmond (molecular dynamics), and Jaguar (quantum chemistry). These tools enable computational chemists, medicinal chemists, and materials scientists to predict molecular properties, optimize drug candidates, and design novel materials with greater speed and accuracy than traditional experimental methods alone. Schrödinger serves a diverse customer base spanning biotech and pharmaceutical companies, academic institutions, and materials science organizations across aerospace, automotive, consumer packaged goods, semiconductors, and specialty chemicals industries. The company's technology addresses critical challenges in small molecule drug discovery, antibody design, peptide discovery, enzyme engineering, drug formulation, polymeric materials, organic electronics, catalysis, and pharmaceutical formulations. Beyond its software business, Schrödinger operates its own therapeutics discovery group that leverages the platform to advance a proprietary pipeline of drug candidates. Current clinical programs include SGR-1505, a MALT1 inhibitor that has received Fast Track designation for relapsed/refractory Waldenström Macroglobulinemia, and SGR-3515, a Wee1/Myt1 inhibitor. The company's mission is to improve human health and quality of life by transforming therapeutic and materials discovery through computational innovation.
Company description Schrodinger official website
Mission. Our mission is to improve human health and quality of life by transforming the way therapeutics and materials are discovered.
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Cloud Saas · Hybrid · On Premise · Other deployment with recorded integration context.
Company milestones
SGR-1505 received Fast Track designation; Phase 1 clinical data for SGR-1505 presented at EHA Annual Congress; Multiple inducement grants reported under Nasdaq rules in 2026
Partnerships
02 · Flagship portfolio
Selected source-backed Company products and the available commercial context.
Antibody and biologics modeling platform
Molecular dynamics simulation engine
Free energy calculations for drug design
Industry-leading ligand-receptor docking solution
Quantum chemistry software
Collaborative molecular design platform
Complete modeling environment for molecular discovery
High-velocity entry point to the Schrödinger platform
Materials science modeling environment
03 · Research intelligence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Nature · Sep 16, 2026
Identifying Cryptic Binding Sites with Mixed Solvent MD Simulation and SiteMap.Journal of chemical information and modeling · Jul 23, 2026
Glass Transition Prediction of Binary Copolymers Across Large Chemical Spaces Using Machine Learning and Physics-Based Modeling.Polymers · Jul 14, 2026
Prioritizing Stability-enhancing Mutations using the ESM Protein Language Model in conjunction with Physics-based MM/GBSA Predictions.Protein engineering, design & selection : PEDS · Jul 6, 2026
Derisking Affinity Optimization for Macrocycles and Cyclic Peptides: High-Precision Free Energy Simulations across Five Diverse Targets.Journal of chemical information and modeling · Jul 3, 2026
Discovery of 2H-Pyrrolo[3,4‑c]pyridin-3-one Derivatives as Type-III c‑MET Inhibitors Enabled by Free-Energy Perturbation Calculations.ACS medicinal chemistry letters · Jun 11, 2026
Clinical validation
No linked records are currently available.
Regulatory
No linked records are currently available.
04 · Company-reported outcomes
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Glide docking across diverse receptor types
Ligand-receptor docking with explicit water modeling
SGR-1505 for Waldenström Macroglobulinemia treatment
Design of a novel small molecule inhibitor of α4β7 integrin using digital chemistry strategy
05 · Leadership
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Recent articles published on Schrodinger's official website.
No Company updates are currently listed.
07 · HAIC coverage
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Curated official destinations from the active Company record.
09 · Market pathway
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.